Follow
Paul N Mainwaring
Paul N Mainwaring
XING Technologies P/L
Verified email at xingtech.com.au - Homepage
Title
Cited by
Cited by
Year
Increased survival with enzalutamide in prostate cancer after chemotherapy
HI Scher, K Fizazi, F Saad, ME Taplin, CN Sternberg, K Miller, R De Wit, ...
New England Journal of Medicine 367 (13), 1187-1197, 2012
51402012
Abiraterone and increased survival in metastatic prostate cancer
JS De Bono, CJ Logothetis, A Molina, K Fizazi, S North, L Chu, KN Chi, ...
New England Journal of Medicine 364 (21), 1995-2005, 2011
49752011
Enzalutamide in metastatic prostate cancer before chemotherapy
TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ...
New England Journal of Medicine 371 (5), 424-433, 2014
32972014
Abiraterone in metastatic prostate cancer without previous chemotherapy
CJ Ryan, MR Smith, JS De Bono, A Molina, CJ Logothetis, P De Souza, ...
New England Journal of Medicine 368 (2), 138-148, 2013
31732013
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo …
K Fizazi, HI Scher, A Molina, CJ Logothetis, KN Chi, RJ Jones, ...
The lancet oncology 13 (10), 983-992, 2012
16672012
Apalutamide treatment and metastasis-free survival in prostate cancer
MR Smith, F Saad, S Chowdhury, S Oudard, BA Hadaschik, JN Graff, ...
New England Journal of Medicine 378 (15), 1408-1418, 2018
13052018
Cabozantinib versus everolimus in advanced renal-cell carcinoma
TK Choueiri, B Escudier, T Powles, PN Mainwaring, BI Rini, F Donskov, ...
New England Journal of Medicine 373 (19), 1814-1823, 2015
12362015
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
TK Choueiri, B Escudier, T Powles, NM Tannir, PN Mainwaring, BI Rini, ...
The lancet oncology 17 (7), 917-927, 2016
10212016
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
ME Gore, C Szczylik, C Porta, S Bracarda, GA Bjarnason, S Oudard, ...
The lancet oncology 10 (8), 757-763, 2009
7062009
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...
The lancet oncology 18 (12), 1688-1700, 2017
6352017
Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial—FIRSTANA
S Oudard, K Fizazi, L Sengeløv, G Daugaard, F Saad, S Hansen, ...
Journal of Clinical Oncology 35 (28), 3189-3197, 2017
3642017
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)
DE Rathkopf, MR Smith, JS De Bono, CJ Logothetis, ND Shore, ...
European urology 66 (5), 815-825, 2014
3442014
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant …
CJ Logothetis, E Basch, A Molina, K Fizazi, SA North, KN Chi, RJ Jones, ...
The lancet oncology 13 (12), 1210-1217, 2012
3232012
Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1.
M Smith, J De Bono, C Sternberg, S Le Moulec, S Oudard, U De Giorgi, ...
LIPPINCOTT WILLIAMS & WILKINS, 2016
2282016
Apalutamide and overall survival in prostate cancer
MR Smith, F Saad, S Chowdhury, S Oudard, BA Hadaschik, JN Graff, ...
European urology 79 (1), 150-158, 2021
2192021
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study …
HJ Schmoll, D Cunningham, A Sobrero, CS Karapetis, P Rougier, ...
Journal of clinical oncology 30 (29), 3588-3595, 2012
2192012
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of …
E Basch, K Autio, CJ Ryan, P Mulders, N Shore, T Kheoh, K Fizazi, ...
The lancet oncology 14 (12), 1193-1199, 2013
2042013
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
ME Gore, C Szczylik, C Porta, S Bracarda, GA Bjarnason, S Oudard, ...
British journal of cancer 113 (1), 12-19, 2015
1992015
Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group.
M Gore, P Mainwaring, R A'hern, V MacFarlane, M Slevin, P Harper, ...
Journal of clinical oncology 16 (7), 2426-2434, 1998
1681998
Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer
A Sobrero, S Ackland, S Clarke, R Perez-Carrión, S Chiara, J Gapski, ...
Oncology 77 (2), 113-119, 2008
1662008
The system can't perform the operation now. Try again later.
Articles 1–20